Blinatumomab belongs to the group of chemotherapeutic drugs “BiTES” or bispecific T-cell engagers.  Blinatumomab is particularly directed to CD19 on B cells and  CD3 on T-cells. This antibody based therapy is produced in CHO cell lines or Chinese hamster ovary cells. 

Blinatumomab engages and activates endogenous T-cells as it is  particularly directed to CD19 on benign and malignant B cells and  CD3in TCR complex  on T-cells. This allows formation of a synapse between the T-cell and the tumor cell, thus upregulating cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T-cells, ultimately resulting in lysis of CD19+ cells. 

Blinatumomab is indicated for the treatment of aadults and pediatric patients one month or older with the following: 

1. CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% . 
2. Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).
3. CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. 

Some of the adverse reactions associated with blinatumomab use include cytokine release syndrome, neurological toxicities, including ICANS (immune effector cell-associated neurotoxicity syndrome), infections, tumor lysis syndrome, neutropenia and febrile neutropenia, effects on ability to drive and use machines, elevated liver enzymes, pancreatitis, leukoencephalopathy

Pricing and availability: 

Blincyto 38.5 mcg Injection in India is usually prescribed by hematologists and oncologists, especially for patients who are candidates for bone marrow transplant (BMT). However, Blincyto is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for blinatumomab is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us. 

The price of Blincyto (blinatumomab) in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy blinatumomab in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access: 

As blinatumomab is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients in the import of blinatumomab India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Each Blincyto package contains:  One blinatumomab for injection 35 mcg single-dose vial and one IV Solution Stabilizer 10 mL single-dose glass vial.  It is administered as an intravenous injection and the dose is as follows: 

1.  Day 1-28:
   • 28 mcg/day for weight > 45 kg 
   • 15 mcg/day for weight < 45 kg.
2. Day 29-42:
   • 14-day treatment interval 

Import process:

1. Request submission for your medicine
   Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
2. Submission of an application (Form 12A)
   Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
3. Verification of documents
   We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
4. Permission to import
   Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
5. Sourcing the medicine
   Our sourcing team connects with authorized global suppliers to find the best blincyto price in India, confirm easy import blinatumomab in India, and ensure authenticity before finalizing the offer.
6. Delivery of the medicine
   After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require: 

To enable the product’s import to India, patients need to provide:

1. A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
2. Recent medical history and test reports (preferably from the last three months), including those confirming the disease. 
3. Government-issued ID proof and proof of residence of the patient.
4. Import permit if applicable.
   

The order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Blincyto from the USA, Canada, Europe, or Australia etc. 
With these steps, patients can import blinatumomab in India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing, and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before being delivered to patients.